DE69926254D1 - Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden - Google Patents
Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptidenInfo
- Publication number
- DE69926254D1 DE69926254D1 DE69926254T DE69926254T DE69926254D1 DE 69926254 D1 DE69926254 D1 DE 69926254D1 DE 69926254 T DE69926254 T DE 69926254T DE 69926254 T DE69926254 T DE 69926254T DE 69926254 D1 DE69926254 D1 DE 69926254D1
- Authority
- DE
- Germany
- Prior art keywords
- beta
- inhibitors
- radioligands
- preparation
- amyloid peptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/968—High energy substrates, e.g. fluorescent, chemiluminescent, radioactive
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10814798P | 1998-11-12 | 1998-11-12 | |
US13128499P | 1999-04-27 | 1999-04-27 | |
PCT/US1999/026715 WO2000028331A1 (en) | 1998-11-12 | 1999-11-12 | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69926254D1 true DE69926254D1 (de) | 2005-08-25 |
Family
ID=26805566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69926254T Expired - Lifetime DE69926254D1 (de) | 1998-11-12 | 1999-11-12 | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden |
Country Status (8)
Country | Link |
---|---|
US (1) | US6331408B1 (de) |
EP (1) | EP1129355B1 (de) |
AT (1) | ATE300052T1 (de) |
AU (1) | AU1618000A (de) |
CA (1) | CA2346099A1 (de) |
DE (1) | DE69926254D1 (de) |
NO (1) | NO20011891L (de) |
WO (1) | WO2000028331A1 (de) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6737038B1 (en) * | 1998-11-12 | 2004-05-18 | Bristol-Myers Squibb Company | Use of small molecule radioligands to discover inhibitors of amyloid-beta peptide production and for diagnostic imaging |
CA2346099A1 (en) * | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
CN1636011A (zh) | 1998-12-24 | 2005-07-06 | 杜邦药品公司 | 作为Aβ蛋白产生抑制剂的琥珀酰氨基苯并二氮杂䓬 |
US6518011B1 (en) * | 1999-01-13 | 2003-02-11 | Bristol-Myers Squibb Company | Method for screening compounds to identify beta-amyloid production modulators |
DE19909357A1 (de) * | 1999-03-03 | 2000-09-07 | Gerd Multhaup | Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt |
EP1261610A2 (de) | 2000-02-17 | 2002-12-04 | Bristol-Myers Squibb Pharma Company | Succinoylamino-carbocyclen und -heterocyclen als hemmer der a-beta-proteinbildung |
EP1268434A1 (de) | 2000-04-03 | 2003-01-02 | Bristol-Myers Squibb Pharma Company | Zyklische lactame als a-beta proteinproduktionsinhibitoren |
WO2001087354A2 (en) * | 2000-05-17 | 2001-11-22 | Bristol-Myers Squibb Pharma Company | Use of small molecule radioligands for diagnostic imaging |
BR0106717A (pt) * | 2000-06-01 | 2002-04-16 | Bristol Myers Squibb Pharma Co | Compostos, composição farmacêutica e usos dos compostos de lactama inovadora |
JP2004535560A (ja) * | 2001-04-20 | 2004-11-25 | ザ ユニヴァーシティ オブ ジョージア リサーチファウンデーション, インク. | 活性部位不活性化因子 |
US20090062256A1 (en) * | 2001-06-01 | 2009-03-05 | Bristol-Myers Squibb Pharma Company | LACTAMS SUBSTITUTED BY CYCLIC SUCCINATES AS INHIBITORS OF Abeta PROTEIN PRODUCTION |
CH698246B1 (de) * | 2001-12-20 | 2009-06-30 | Hoffmann La Roche | Test zur Identifizierung von Inhibitoren von Beta-Sekretasen. |
CA2589860A1 (en) * | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
EP2235058A2 (de) | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anti-amyloid-antikörper und ihre verwendung |
TWI530489B (zh) | 2011-03-22 | 2016-04-21 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯二氮呯酮化合物 |
US9427442B2 (en) | 2012-09-21 | 2016-08-30 | Bristol-Myers Squibb Company | Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds |
JP2015529250A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | フルオロアルキルジベンゾジアゼピノン化合物 |
US9187434B2 (en) | 2012-09-21 | 2015-11-17 | Bristol-Myers Squibb Company | Substituted 1,5-benzodiazepinones compounds |
CN104797584A (zh) | 2012-09-21 | 2015-07-22 | 百时美施贵宝公司 | 作为notch抑制剂的三环杂环化合物 |
JP2015529252A (ja) | 2012-09-21 | 2015-10-05 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | フルオロアルキル−1,4−ベンゾジアゼピノン化合物 |
JP2015534554A (ja) | 2012-09-21 | 2015-12-03 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | アルキル,フルオロアルキル−1,4−ベンゾジアゼピノン化合物 |
JP2015533811A (ja) | 2012-09-21 | 2015-11-26 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | N−置換ビス(フルオロアルキル)1,4−ベンゾジアゼピノン化合物 |
TWI614238B (zh) * | 2012-09-21 | 2018-02-11 | 必治妥美雅史谷比公司 | 雙(氟烷基)-1,4-苯并二氮呯酮化合物及其前藥 |
WO2014047391A1 (en) | 2012-09-21 | 2014-03-27 | Bristol-Myers Squibb Company | Prodrugs of 1,4-benzodiazepinone compounds |
EP2981267A1 (de) | 2013-04-04 | 2016-02-10 | Bristol-Myers Squibb Company | Kombinationstherapie zur behandlung von proliferativen erkrankungen |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZW23187A1 (en) * | 1986-12-15 | 1988-06-29 | Hoffmann La Roche | Phosphinic acid derivatives |
US5252463A (en) * | 1990-06-22 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Clipsin, a chymotrypsin-like protease and method of using same |
GB9022117D0 (en) * | 1990-10-11 | 1990-11-21 | Beecham Group Plc | Novel compounds |
US5434050A (en) * | 1991-08-13 | 1995-07-18 | Regents Of The University Of Minnesota | Labelled β-amyloid peptide and methods of screening for Alzheimer's disease |
US5538845A (en) * | 1992-02-05 | 1996-07-23 | Athena Neurosciences, Inc. | Beta-amyloid peptide production inhibitors and methods for their identification |
US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
US5552419A (en) * | 1993-01-06 | 1996-09-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
US5506242A (en) * | 1993-01-06 | 1996-04-09 | Ciba-Geigy Corporation | Arylsufonamido-substituted hydroxamic acids |
US5594006A (en) * | 1993-03-18 | 1997-01-14 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives as matrix metalloproteinases inhibitors |
AU6909194A (en) * | 1993-05-14 | 1994-12-12 | Board Of Regents, The University Of Texas System | Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole |
ZA945719B (en) * | 1993-08-09 | 1996-02-01 | Lilly Co Eli | Identification and use of protease inhibitors |
US5514716A (en) * | 1994-02-25 | 1996-05-07 | Sterling Winthrop, Inc. | Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof |
US5672598A (en) * | 1995-03-21 | 1997-09-30 | The Procter & Gamble Company | Lactam-containing hydroxamic acids |
WO1996040885A2 (en) * | 1995-06-07 | 1996-12-19 | Athena Neurosciences, Inc. | β-SECRETASE, ANTIBODIES TO β-SECRETASE, AND ASSAYS FOR DETECTING β-SECRETASE INHIBITION |
US5703129A (en) * | 1996-09-30 | 1997-12-30 | Bristol-Myers Squibb Company | 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production |
WO1998015828A1 (en) * | 1996-10-07 | 1998-04-16 | Scios Inc. | Method to identify direct inhibitors of the beta-amyloid forming enzyme gamma-secretase |
US5734054A (en) * | 1996-11-05 | 1998-03-31 | Pharmacopeia, Inc. | Hydroxy-amino acid amides |
CA2346099A1 (en) * | 1998-11-12 | 2000-05-18 | Dupont Pharmaceuticals Company | Use of radioligands to screen inhibitors of amyloid-beta peptide production |
-
1999
- 1999-11-12 CA CA002346099A patent/CA2346099A1/en not_active Abandoned
- 1999-11-12 WO PCT/US1999/026715 patent/WO2000028331A1/en active IP Right Grant
- 1999-11-12 EP EP99958905A patent/EP1129355B1/de not_active Expired - Lifetime
- 1999-11-12 AU AU16180/00A patent/AU1618000A/en not_active Abandoned
- 1999-11-12 US US09/438,901 patent/US6331408B1/en not_active Expired - Lifetime
- 1999-11-12 DE DE69926254T patent/DE69926254D1/de not_active Expired - Lifetime
- 1999-11-12 AT AT99958905T patent/ATE300052T1/de not_active IP Right Cessation
-
2001
- 2001-04-17 NO NO20011891A patent/NO20011891L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2346099A1 (en) | 2000-05-18 |
EP1129355B1 (de) | 2005-07-20 |
NO20011891L (no) | 2001-07-02 |
AU1618000A (en) | 2000-05-29 |
NO20011891D0 (no) | 2001-04-17 |
EP1129355A1 (de) | 2001-09-05 |
US6331408B1 (en) | 2001-12-18 |
ATE300052T1 (de) | 2005-08-15 |
WO2000028331A1 (en) | 2000-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69926254D1 (de) | Verwendung von radioliganden zum screening von inhibitoren der herstellung von beta-amyloid peptiden | |
ATE211129T1 (de) | Inhibitoren von beta-amyloid-protein-herstellung | |
ATE239797T1 (de) | Antikörper gegen beta-amyloid oder derivative davon und seine verwendung | |
MY131442A (en) | Excitatory amino acid receptor antagonists | |
ATE491721T1 (de) | Zusammensetzung und verfahren zum nachweis von krankheiten in zusammenhang mit der bildung von amyloid-ähnlichen fibrillen oder protein- aggregaten | |
EA200401365A1 (ru) | Способы лечения илеуса | |
NO20006645D0 (no) | Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme | |
WO2001087354A3 (en) | Use of small molecule radioligands for diagnostic imaging | |
DE69025472D1 (de) | Dopamin-agonisten | |
DE69530933D1 (de) | Verwendung von 5-(tetradecyloxy)-2-furan carbonsäure für die behandlung von alzheimer krankheit oder psychosis | |
RO116898B1 (ro) | Derivaţi de dioxizi de benzotiazină, procedeu pentru prepararea acestora, intermediari, compoziţie farmaceutică şi metodă pentru inhibarea nivelurilor crescute de endotelină | |
DE60035693D1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
DK1373502T3 (da) | Dopaminerge neuronale overlevelsesfremmende faktorer og avendelser heraf | |
NO20051664L (no) | Behandling av demens og Parkinsons sykdom | |
DE69808475D1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
MY120085A (en) | Pyrido-thieno-diazepines, method for the production thereof and pharmaceutical compositions containing said pyrido-thieno-diazepines. | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
WO1999006838A3 (en) | Novel method of detecting amyloid-like fibrils or protein aggregates | |
WO2003045325A3 (en) | Dopaminergic stimulatory factor | |
DE60235161D1 (de) | Methoden und zusammensetzungen zur identifikation von gen-funktion | |
ATE420637T1 (de) | Verwendung von 1,2-diazadibenzoäe,hüazulenen zur herstellung von pharmazeutischen formulierungen für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems | |
WO2002048102A3 (fr) | Isocoumarines inhibitrices de la production de peptide amyloide, preparation, compositions les contenant et utilisations |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |